Your browser doesn't support javascript.
Incidence of symptomatic Covid-19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population.
Graf, Irene; Herndlhofer, Susanne; Kundi, Michael; Greiner, Georg; Sperr, Martina; Hadzijusufovic, Emir; Valent, Peter; Sperr, Wolfgang R.
  • Graf I; Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
  • Herndlhofer S; Ludwig Boltzmann Institute of Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
  • Kundi M; Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
  • Greiner G; Ludwig Boltzmann Institute of Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
  • Sperr M; Institute of Environmental Health, Medical University of Vienna, Vienna, Austria.
  • Hadzijusufovic E; Ihr Labor, Medical Diagnostic Laboratories, Vienna, Austria.
  • Valent P; Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
  • Sperr WR; Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Eur J Haematol ; 110(1): 67-76, 2023 Jan.
Article in English | MEDLINE | ID: covidwho-2323348
ABSTRACT

BACKGROUND:

The SARS-COV-2 (Covid-19) pandemic has impacted the management of patients with hematologic disorders. In some entities, an increased risk for Covid-19 infections was reported, whereas others including chronic myeloid leukemia (CML) had a lower mortality. We have analyzed the prevalence of Covid-19 infections in patients with mastocytosis during the Covid-19 pandemic in comparison to data from CML patients and the general Austrian population. MATERIALS AND

METHODS:

The prevalence of infections and PCR-proven Covid-19 infections was analyzed in 92 patients with mastocytosis. As controls, we used 113 patients with CML and the expected prevalence of Covid-19 in the general Austrian population.

RESULTS:

In 25% of the patients with mastocytosis (23/92) signs and symptoms of infection, including fever (n = 11), dry cough (n = 10), sore throat (n = 12), pneumonia (n = 1), and dyspnea (n = 3) were recorded. Two (8.7%) of these symptomatic patients had a PCR-proven Covid-19 infection. Thus, the prevalence of Covid-19 infections in mastocytosis was 2.2%. The number of comorbidities, subtype of mastocytosis, regular exercise, smoking habits, age, or duration of disease at the time of interview did not differ significantly between patients with and without Covid-19 infections. In the CML cohort, 23.9% (27/113) of patients reported signs and symptoms of infection (fever, n = 8; dry cough, n = 17; sore throat, n = 11; dyspnea, n = 5). Six (22.2%) of the symptomatic patients had a PCR-proven Covid-19 infection. The prevalence of Covid-19 in all CML patients was 5.3%. The observed number of Covid-19 infections neither in mastocytosis nor in CML patients differed significantly from the expected number of Covid-19 infections in the Austrian population.

CONCLUSIONS:

Our data show no significant difference in the prevalence of Covid-19 infections among patients with mastocytosis, CML, and the general Austrian population and thus, in mastocytosis, the risk of a Covid-19 infection was not increased compared to the general population.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Mastocytosis / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Pharyngitis / Leukemia, Myeloid / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Limits: Humans Country/Region as subject: Europa Language: English Journal: Eur J Haematol Journal subject: Hematology Year: 2023 Document Type: Article Affiliation country: Ejh.13875

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Mastocytosis / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Pharyngitis / Leukemia, Myeloid / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Limits: Humans Country/Region as subject: Europa Language: English Journal: Eur J Haematol Journal subject: Hematology Year: 2023 Document Type: Article Affiliation country: Ejh.13875